Us2

is a fully automated AI platform for analysis and interpretation of echocardiograms, including both 2D video and Doppler images.

[Us2 @us2_ai]

🚗 Heading to #ASE26?

Come and meet the https://t.co/LR5so3R0R3 team in Colorado!

We'll be onsite from 26–28 June with live scanning and a chance to see firsthand how AI is elevating echocardiography in clinical workflows around the world.

💡 See how https://t.co/LR5so3R0R3 can elevate your echo workflow:
✔ Consistent, accurate and faster echocardiogram analysis
✔ Improved diagnostic efficiency
✔ The latest innovations in cardiovascular imaging

📍 You can find us at the following partner booths:
Merge: Booth #903
@viz_ai: Booth #622

See you in Colorado!

#ASE26 #AIEcho #AI #Cardiology #Echocardiography

[Us2 @us2_ai]

𝐖𝐡𝐞𝐫𝐞 𝐰𝐚𝐬 𝐔𝐬2.𝐚𝐢 𝐭𝐡𝐢𝐬 𝐰𝐞𝐞𝐤𝐞𝐧𝐝? 𝐌𝐢𝐥𝐚𝐧. 🇮🇹

Our co-founder Yoran Hummel attended "Smarter, Faster, Better: How AI is Reshaping the Echocardiography Workflow" at San Luca Hospital, a one-day course fully dedicated to AI and echocardiography. He also gave a presentation and led a two-hour hands-on workshop, giving attendees the opportunity to experience https://t.co/LR5so3Qt1v firsthand.

Being in the room with clinicians, scientists and fellow technology developers was a reminder of how much the field is shifting. A few things stood out:

➡️ The conversation has moved on. The question is no longer whether AI works. It is how to implement it responsibly, equitably and effectively in routine clinical practice.

➡️ Standardisation is the real opportunity. AI's ability to reduce variability, improve reproducibility and support less experienced operators is where the greatest clinical value lies.

➡️ End-to-end workflows are the future. AI is evolving beyond automated measurements toward full workflow support including image acquisition, quality control, structured reporting and disease detection.

➡️ Vendor agnosticism and interoperability are non-negotiable. Future AI solutions must integrate echocardiography with multimodality imaging, clinical information and outcomes data to support truly patient-centred care.

At https://t.co/LR5so3Qt1v, these are not aspirations. They are what we build toward every day.

We are grateful to have had the opportunity to participate in this educational event and to put our technology directly in the hands of clinicians. There is no better way to understand what the field needs than by being in the room.

A huge thank you to course directors Luigi Badano, Denisa Muraru and Marco Penso for creating such a focused and thoughtful space for this conversation.

[Us2 @us2_ai]

Attending ESC Cardio-Oncology today?

https://t.co/LR5so3Qt1v's deep learning echo workflow validated in a real-world cardio-oncology cohort of 282 patients. Strong accuracy. Consistent across key subgroups.

📍 Moderated ePoster 1 at 13:15 CET today.

Find https://t.co/LR5so3Qt1v at Stand A6 to discover how our solution can fit into your cardio-oncology echo workflow!

#ESCardioOnco26

[Us2 @us2_ai]

📹𝐁𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡: 𝐃𝐫. 𝐉𝐞𝐫𝐞𝐦𝐲 𝐒𝐥𝐢𝐯𝐧𝐢𝐜𝐤 𝐨𝐧 𝐦𝐮𝐥𝐭𝐢𝐦𝐨𝐝𝐚𝐥 𝐀𝐈 𝐚𝐧𝐝 𝐰𝐡𝐚𝐭 𝐢𝐭 𝐦𝐞𝐚𝐧𝐬 𝐟𝐨𝐫 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧.

Echo is already the frontline screening tool for cardiac amyloidosis. But echo labs are busy. That's where AI echo comes in — making detection more scalable, accurate and efficient.

In this interview, Dr. Slivnick, lead author of the study published in Circulation: Cardiovascular Imaging, explains why combining https://t.co/LR5so3R0R3's AI echo model with clinical and laboratory data was designed to mirror what clinicians already do in practice. And what the results mean for the future of CA screening.

Watch the full interview!

[Us2 @us2_ai]

𝐔𝐬2.𝐚𝐢 𝐢𝐬 𝐚𝐭 𝐄𝐒𝐂 𝐂𝐚𝐫𝐝𝐢𝐨-𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 𝐭𝐡𝐢𝐬 𝐰𝐞𝐞𝐤!

📍Stand A6

Come find us and talk about how AI echo can support your cardio-oncology workflow. Consistent measurements, early detection, subtle changes tracked over time!

#ESCardioOnco26

[Us2 @us2_ai]

Dr. Jasper Tromp led an economic evaluation of AI-assisted LVEF assessment in Singapore. 𝐓𝐡𝐞 𝐜𝐨𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧: 𝐀𝐈-𝐩𝐨𝐰𝐞𝐫𝐞𝐝 𝐩𝐨𝐢𝐧𝐭-𝐨𝐟-𝐜𝐚𝐫𝐞 𝐮𝐥𝐭𝐫𝐚𝐬𝐨𝐮𝐧𝐝 𝐢𝐬 𝐧𝐨𝐭 𝐣𝐮𝐬𝐭 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐚𝐜𝐜𝐮𝐫𝐚𝐭𝐞 — 𝐢𝐭'𝐬 𝐚 💰𝐜𝐨𝐬𝐭-𝐬𝐚𝐯𝐢𝐧𝐠💰 𝐩𝐚𝐭𝐡 𝐟𝐨𝐫 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐜𝐚𝐫𝐞.

Published in ESC Heart Failure, the study looked at the cost of AI-assisted LVEF assessment using https://t.co/LR5so3R0R3, performed by novices, versus standard sonographer-led echocardiography in Singapore.

Same diagnostic accuracy. Significantly lower cost.

Dr. Tromp, Assistant Professor at the Saw Swee Hock School of Public Health, National University of Singapore, shares what this means for healthcare systems where echocardiographic capacity is limited and heart failure is on the rise.

We are proud to have https://t.co/LR5so3R0R3 as the AI echo software featured in this work!

🔗 Full study: https://t.co/1yTfLizUd7

[Us2 @us2_ai]

𝐓𝐡𝐢𝐬 𝐢𝐬 𝐔𝐬2.𝐚𝐢. 𝐖𝐡𝐨 𝐰𝐞 𝐚𝐫𝐞, 𝐰𝐡𝐲 𝐰𝐞 𝐛𝐮𝐢𝐥𝐭 𝐢𝐭, 𝐚𝐧𝐝 𝐰𝐡𝐚𝐭 𝐢𝐭 𝐦𝐞𝐚𝐧𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐞𝐜𝐡𝐨𝐜𝐚𝐫𝐝𝐢𝐨𝐠𝐫𝐚𝐩𝐡𝐲.

At the heart of everything we do is a simple mission: make echocardiography analysis more accurate, more efficient and more accessible for clinicians and patients around the world.

"The gain that you get, the reduction of error in reducing variability of day to day measurements doesn't even speak to the other benefits of using an AI echo platform like this, and the efficiency gains in throughput in a lab, is incredibly amazing." – Dr. Ken Stein

If you are new to https://t.co/LR5so3R0R3 or just curious about what we are building, this is the best place to start.
👉 Book a demo at https://t.co/yLoT3CRG8w

[Us2 @us2_ai]

‼️ 93% 𝐬𝐞𝐧𝐬𝐢𝐭𝐢𝐯𝐢𝐭𝐲. 𝐙𝐞𝐫𝐨 𝐢𝐧𝐝𝐞𝐭𝐞𝐫𝐦𝐢𝐧𝐚𝐭𝐞 𝐜𝐚𝐬𝐞𝐬. 𝐓𝐡𝐢𝐬 𝐢𝐬 𝐰𝐡𝐚𝐭 𝐦𝐮𝐥𝐭𝐢𝐦𝐨𝐝𝐚𝐥 𝐀𝐈 𝐥𝐨𝐨𝐤𝐬 𝐥𝐢𝐤𝐞 𝐟𝐨𝐫 𝐚𝐦𝐲𝐥𝐨𝐢𝐝 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧.

https://t.co/LR5so3R0R3's cardiac amyloidosis AI model is already FDA-cleared and CE marked for CA detection from a single echo view. But a new study in Circulation: Cardiovascular Imaging asked: could adding clinical and laboratory data make it even better?

𝐓𝐡𝐞 𝐚𝐧𝐬𝐰𝐞𝐫 𝐰𝐚𝐬 𝐲𝐞𝐬.

Tested and validated in a multicenter, international cohort of 1,043 patients across 9 sites, the model combined https://t.co/atBYE0GB0J's deep learning output with demographics, lab biomarkers and TTE parameters.

🟢 AUC improved from 0.89 to 0.94.
🟢Sensitivity improved from 76% to 93%.
🟢Indeterminate cases eliminated entirely.

The first study to fuse deep learning TTE AI with multimodal clinical data for cardiac amyloidosis detection.

https://t.co/LR5so3R0R3 is proud to have been central to this work. Congratulations to the entire team.

🔗 Full paper: https://t.co/WfbGNEZXkF

[Us2 @us2_ai]

Workflow integration and not knowing where to start are the biggest barriers to AI echo adoption.

The hesitation isn't financial. It's uncertainty.

https://t.co/LR5so3Qt1v is vendor agnostic, with partnerships across OEMs, AI platforms and PACS systems. Whatever your setup, there is a pathway for you.

The benefits, faster reporting, earlier detection, reduced sonographer burden and better patient outcomes, are well worth taking that first step.

If you are not sure where to start, we are here to help. Reach out to us today and let's begin your AI echo journey together.

👉 Book a demo at https://t.co/yLoT3CR8iY

[Us2 @us2_ai]

💵 99.9% 𝐩𝐫𝐨𝐛𝐚𝐛𝐢𝐥𝐢𝐭𝐲. 𝐓𝐡𝐚𝐭'𝐬 𝐡𝐨𝐰 𝐥𝐢𝐤𝐞𝐥𝐲 𝐚 𝐧𝐨𝐯𝐢𝐜𝐞-𝐥𝐞𝐝 𝐀𝐈-𝐏𝐎𝐂 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐢𝐬 𝐭𝐨 𝐛𝐞 𝐜𝐨𝐬𝐭-𝐬𝐚𝐯𝐢𝐧𝐠 𝐜𝐨𝐦𝐩𝐚𝐫𝐞𝐝 𝐭𝐨 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝 𝐓𝐓𝐄. 𝐓𝐡𝐚𝐭'𝐬 𝐧𝐨𝐭 𝐚 𝐦𝐚𝐫𝐤𝐞𝐭𝐢𝐧𝐠 𝐜𝐥𝐚𝐢𝐦. 𝐓𝐡𝐚𝐭'𝐬 𝐚 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐟𝐢𝐧𝐝𝐢𝐧𝐠 𝐢𝐧 𝐄𝐒𝐂 𝐇𝐞𝐚𝐫𝐭 𝐅𝐚𝐢𝐥𝐮𝐫𝐞.

A new economic evaluation looked at the cost of AI-assisted LVEF assessment using https://t.co/LR5so3R0R3, performed by novices, versus standard sonographer-led echocardiography in Singapore.

The AI-POC pathway cost US$1,422 per patient, compared to US$1,684 for conventional TTE, a saving of US$26,013 per 100 patients at a single centre.

This study is specific to Singapore's healthcare system. But the methodology is transferable. Research teams in other countries can apply the same framework using their own local cost and epidemiological data to understand what AI-POC task-shifting could mean for their health system.

The economic case for AI echo is no longer just theoretical!

🔗 https://t.co/1yTfLizUd7

[Us2 @us2_ai]

𝐎𝐮𝐫 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐚𝐭 𝐇𝐚𝐫𝐫𝐢𝐬𝐨𝐧.𝐚𝐢 𝐣𝐮𝐬𝐭 𝐦𝐚𝐝𝐞 𝐅𝐨𝐫𝐛𝐞𝐬 𝐀𝐬𝐢𝐚. 𝐀𝐧𝐝 𝐰𝐞 𝐠𝐨𝐭 𝐚 𝐦𝐞𝐧𝐭𝐢𝐨𝐧.🌏

Forbes Asia's latest Editors' Pick features Dr Aengus Tran, co-founder and CEO of @Harrison_ai. In the piece, https://t.co/H3E6KD6sId's decision to include https://t.co/LR5so3R0R3 on its platform is highlighted, recognising https://t.co/LR5so3R0R3 as a trusted solution for AI-powered cardiac ultrasound analysis.

We are proud to be part of the https://t.co/H3E6KD6sId ecosystem and to be bringing AI echo to an even wider network of clinicians and healthcare institutions globally.

Interested in learning more about how https://t.co/LR5so3R0R3 works within the https://t.co/H3E6KD6sId platform? Drop us a message!

🔗https://t.co/MkcV9cgwbJ

[Us2 @us2_ai]

🤝 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐨𝐮𝐫 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬!

Did you know https://t.co/LR5so3Qt1v is vendor-neutral? We are partnered with leading OEM and device companies, integrated into AI platforms and PACS systems, and supported by distributors across the globe.

Because AI echo shouldn't be locked into one device, one platform or one workflow. It should work wherever clinicians need it.

Explore the full list of partners at the link below.

🔗 https://t.co/gLr5s6G5kr

[Us2 @us2_ai]

🔢 𝐅𝐢𝐠𝐮𝐫𝐢𝐧𝐠 𝐨𝐮𝐭 𝐭𝐡𝐞 𝐑𝐎𝐈 𝐨𝐟 𝐀𝐈 𝐞𝐜𝐡𝐨 𝐟𝐨𝐫 𝐲𝐨𝐮𝐫 𝐥𝐚𝐛 𝐣𝐮𝐬𝐭 𝐠𝐨𝐭 𝐚 𝐥𝐨𝐭 𝐞𝐚𝐬𝐢𝐞𝐫.

Most labs see measurable returns 𝐰𝐢𝐭𝐡𝐢𝐧 𝐦𝐨𝐧𝐭𝐡𝐬, not years.

The hesitation is rarely about budget. It's about not knowing what the numbers look like for your specific lab.

That's exactly what https://t.co/LR5so3R0R3's ROI Calculator was built for. Plug in your volume, your time per scan and your reimbursement rate. Get a clear projection in seconds.

No assumptions. No sales pitch. Just your numbers.

👉 https://t.co/fxqZW99G2o

[Us2 @us2_ai]

🔬 Scientific Presentations ft https://t.co/LR5so3Qt1v at #HeartFailure26 | 4 of 4

A geriatrician achieved results comparable to an expert cardiologist using https://t.co/LR5so3Qt1v's AI analysis software for LVEF assessment in a Paris geriatric unit.👵👴

AI is expanding who can perform cardiac imaging. And where.

🔗 Full abstract: https://t.co/9MsBu9lya0

[Us2 @us2_ai]

🔬 Scientific Presentations ft https://t.co/LR5so3R0R3 at #HeartFailure26 | 3 of 4

700+ 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬. 𝐌𝐞𝐭𝐫𝐨𝐩𝐨𝐥𝐢𝐭𝐚𝐧 𝐚𝐧𝐝 𝐫𝐮𝐫𝐚𝐥-𝐫𝐞𝐦𝐨𝐭𝐞 𝐜𝐥𝐢𝐧𝐢𝐜𝐬 𝐚𝐜𝐫𝐨𝐬𝐬 𝐀𝐮𝐬𝐭𝐫𝐚𝐥𝐢𝐚. 𝐒𝐜𝐫𝐞𝐞𝐧𝐞𝐝 𝐟𝐨𝐫 𝐮𝐧𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐞𝐝 𝐡𝐞𝐚𝐫𝐭 𝐟𝐚𝐢𝐥𝐮𝐫𝐞. 𝐁𝐲 𝐩𝐫𝐚𝐜𝐭𝐢𝐜𝐞 𝐧𝐮𝐫𝐬𝐞𝐬. 𝐖𝐢𝐭𝐡 𝐀𝐈.

🧑‍⚕️ 👩‍⚕️ Not cardiologists. Not specialist echo labs. Practice nurses in everyday GP clinics, using AI-powered portable ultrasound to find heart failure earlier than ever before.

And it worked.

⏭️ This is what democratising cardiac diagnostics looks like. AI doing the heavy lifting. Nurses empowered to do more. Patients in rural and remote communities getting access to cardiac screening they would never otherwise receive.

The full results from 700+ patients are coming in August 2026.

https://t.co/LR5so3R0R3 is proud to power this work. 💙

🔗 https://t.co/hxjplz6E4o

If you work in primary care, nursing or health policy — this one is for you. Tag someone who needs to see this.

[Us2 @us2_ai]

🔬 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧𝐬 𝐟𝐭. 𝐔𝐬2.𝐚𝐢 𝐟𝐫𝐨𝐦 #HeartFailure26 | 2 𝐨𝐟 4

Heart failure remains chronically undetected in primary care. Even among high-risk patients with hypertension and diabetes.

The PANACEA-HF study tested an AI-powered clinical algorithm combining PoCUS, NT-proBNP and ESC criteria across primary care clinics in Australia.

→ GPs using clinical judgement alone: 100% sensitivity. 88.8% specificity. 29 referrals. 9 false positives.

🟢 𝐀𝐈-𝐩𝐨𝐰𝐞𝐫𝐞𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐚𝐥𝐠𝐨𝐫𝐢𝐭𝐡𝐦: 96.7% sensitivity. 98.8% specificity. 20 referrals. 1 false positive.

𝐅𝐞𝐰𝐞𝐫 𝐮𝐧𝐧𝐞𝐜𝐞𝐬𝐬𝐚𝐫𝐲 𝐫𝐞𝐟𝐞𝐫𝐫𝐚𝐥𝐬. 𝐍𝐞𝐚𝐫-𝐢𝐝𝐞𝐧𝐭𝐢𝐜𝐚𝐥 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧. 𝐀 𝐬𝐦𝐚𝐫𝐭𝐞𝐫 𝐮𝐬𝐞 𝐨𝐟 𝐬𝐩𝐞𝐜𝐢𝐚𝐥𝐢𝐬𝐭 𝐫𝐞𝐬𝐨𝐮𝐫𝐜𝐞𝐬.

Full results from 700+ patients coming August 2026.

🔗 https://t.co/c1p4FRPmVa

[Us2 @us2_ai]

🔬 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧𝐬 𝐟𝐭. 𝐔𝐬2.𝐚𝐢 𝐟𝐫𝐨𝐦 𝐇𝐞𝐚𝐫𝐭 𝐅𝐚𝐢𝐥𝐮𝐫𝐞 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 2026 | 1 𝐨𝐟 4

AI echo doesn't just help patients. It also helps the planet! 🌏

Presented at #HeartFailure26, the Heart2Miss study showed AI-powered cardiac triage at primary care level makes a real environmental difference.

Across 716 patients:
→ 53% reduction in distance travelled per patient.
→ 39% fewer carbon emissions.
→ 77.4% of patients needed no further cardiac testing beyond primary care.

Decentralising cardiac diagnostics isn't just clinically effective. It's environmentally responsible and directly aligned with upcoming strategic commitments to sustainability.

This is what AI echo beyond the hospital looks like.

🔗 View the poster: https://t.co/EtKfiPdoGh

[Us2 @us2_ai]

📖Methods paper published in EHJ: https://t.co/UYbOeabYLO

[Us2 @us2_ai]

🗣️ "𝐈𝐟 𝐈 𝐡𝐚𝐝𝐧'𝐭 𝐠𝐨𝐭 𝐭𝐡𝐞 𝐬𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐝𝐨𝐧𝐞, 𝐈'𝐝 𝐬𝐭𝐢𝐥𝐥 𝐛𝐞 𝐰𝐚𝐢𝐭𝐢𝐧𝐠 𝐟𝐨𝐫 𝐚 𝐡𝐨𝐬𝐩𝐢𝐭𝐚𝐥 𝐚𝐩𝐩𝐨𝐢𝐧𝐭𝐦𝐞𝐧𝐭. 𝐎𝐧𝐞 𝐝𝐚𝐲 𝐢𝐭 𝐰𝐨𝐮𝐥𝐝 𝐡𝐚𝐯𝐞 𝐛𝐞𝐞𝐧 𝐭𝐨𝐨 𝐥𝐚𝐭𝐞. 𝐄𝐯𝐞𝐫𝐭𝐨𝐧 — 𝐭𝐡𝐞𝐲'𝐯𝐞 𝐬𝐚𝐯𝐞𝐝 𝐦𝐲 𝐥𝐢𝐟𝐞."

A finger-prick blood test flagged elevated NT-proBNP followed by an AI-assisted echocardiogram, powered by https://t.co/LR5so3R0R3, found life-threatening heart failure the same day.

🩺 𝐓𝐡𝐞 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬: 𝐡𝐞𝐚𝐫𝐭 𝐟𝐚𝐢𝐥𝐮𝐫𝐞 𝐰𝐢𝐭𝐡 𝐫𝐞𝐝𝐮𝐜𝐞𝐝 𝐞𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐟𝐫𝐚𝐜𝐭𝐢𝐨𝐧. 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐰𝐚𝐬 𝐬𝐭𝐚𝐫𝐭𝐞𝐝 𝐭𝐡𝐞 𝐬𝐚𝐦𝐞 𝐝𝐚𝐲.

❌ No GP referral. No waiting list. No hospital appointment needed.

This is what early detection looks like when healthcare comes to the community.

A huge thank you to the entire BEAT Breathlessness team for choosing https://t.co/LR5so3R0R3 as the AI echo solution at the heart of this programme. Stories like Gina's are exactly why we do what we do. 🧡 💙

[Us2 @us2_ai]

🗣️Gina's full story: https://t.co/XQbabP9wZL